STOCK TITAN

[8-K] Air Products & Chemicals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

A Form 4 filed on 07/08/2025 discloses that Stephen Neeleman, founder, Vice-Chairman and director of HealthEquity, Inc. (HQY), disposed of 1,049 common shares on 07/03/2025 at an average price of $100.8721 under transaction code "F", indicating shares were withheld to satisfy taxes or exercise costs rather than an open-market sale.

After the withholding, Neeleman continues to hold 112,593 shares directly and 756,235 shares indirectly through a trust and family LLC, leaving his total ownership at approximately 868,828 shares. The disposition equals roughly 0.12 % of his aggregate holdings, suggesting no material change in insider alignment.

Table II shows three fully vested option grants with strike prices of $41.28, $61.72 and $73.61, covering a combined 49,462 shares that remain outstanding and immediately exercisable.

No other share sales, purchases or derivative exercises were reported. Given the small size and tax-related nature of the transaction, the filing is operationally and financially immaterial for HQY shareholders.

Un modulo Form 4 presentato il 08/07/2025 rivela che Stephen Neeleman, fondatore, vicepresidente e direttore di HealthEquity, Inc. (HQY), ha ceduto 1.049 azioni ordinarie il 03/07/2025 a un prezzo medio di $100,8721 con codice di transazione "F", indicando che le azioni sono state trattenute per coprire tasse o costi di esercizio, e non vendute sul mercato aperto.

Dopo questa trattenuta, Neeleman detiene ancora direttamente 112.593 azioni e 756.235 azioni indirettamente tramite un trust e una LLC familiare, portando la sua proprietà totale a circa 868.828 azioni. La cessione rappresenta circa lo 0,12% del suo patrimonio complessivo, suggerendo nessun cambiamento significativo nell’allineamento interno.

La Tabella II mostra tre opzioni completamente maturate con prezzi di esercizio di $41,28, $61,72 e $73,61, relative a un totale combinato di 49.462 azioni ancora in essere e immediatamente esercitabili.

Non sono state segnalate altre vendite, acquisti o esercizi di derivati. Considerata la dimensione ridotta e la natura fiscale della transazione, la comunicazione è operativamente e finanziariamente irrilevante per gli azionisti di HQY.

Un Formulario 4 presentado el 08/07/2025 revela que Stephen Neeleman, fundador, vicepresidente y director de HealthEquity, Inc. (HQY), dispuso de 1,049 acciones ordinarias el 03/07/2025 a un precio promedio de $100.8721 bajo el código de transacción "F", lo que indica que las acciones fueron retenidas para cubrir impuestos o costos de ejercicio y no vendidas en el mercado abierto.

Tras la retención, Neeleman sigue poseyendo 112,593 acciones directamente y 756,235 acciones indirectamente a través de un fideicomiso y una LLC familiar, dejando su propiedad total en aproximadamente 868,828 acciones. La disposición representa aproximadamente el 0,12 % de su tenencia total, lo que sugiere que no hay un cambio material en la alineación interna.

La Tabla II muestra tres concesiones de opciones completamente adquiridas con precios de ejercicio de $41.28, $61.72 y $73.61, que cubren un total combinado de 49,462 acciones que permanecen vigentes y son inmediatamente ejercitables.

No se reportaron otras ventas, compras o ejercicios de derivados. Dado el tamaño reducido y la naturaleza relacionada con impuestos de la transacción, la presentación es operativa y financieramente insignificante para los accionistas de HQY.

2025년 7월 8일 제출된 Form 4에 따르면, HealthEquity, Inc. (HQY)의 창립자이자 부회장 겸 이사인 Stephen Neeleman이 2025년 7월 3일에 평균 가격 $100.87211,049주 보통주를 처분했으며, 거래 코드 "F"는 주식이 공개 시장에서 판매된 것이 아니라 세금 납부나 행사 비용 충당을 위해 원천징수되었음을 나타냅니다.

원천징수 후, Neeleman은 직접 112,593주와 신탁 및 가족 LLC를 통해 간접적으로 756,235주를 계속 보유하여 총 소유 주식 수가 약 868,828주에 이릅니다. 이번 처분은 전체 보유 주식의 약 0.12%에 해당하며, 내부자 지분 변동이 크지 않음을 시사합니다.

표 II에는 행사가격이 각각 $41.28, $61.72, $73.61인 완전히 취득된 세 가지 옵션 부여가 나와 있으며, 총 49,462주가 아직 남아 즉시 행사 가능합니다.

다른 주식 매도, 매수 또는 파생상품 행사는 보고되지 않았습니다. 거래 규모가 작고 세금 관련 거래임을 고려할 때, 이 신고는 HQY 주주들에게 운영적 및 재무적으로 중요하지 않은 사항입니다.

Un formulaire 4 déposé le 08/07/2025 révèle que Stephen Neeleman, fondateur, vice-président et administrateur de HealthEquity, Inc. (HQY), a cédé 1 049 actions ordinaires le 03/07/2025 à un prix moyen de 100,8721 $ sous le code de transaction "F", indiquant que les actions ont été retenues pour couvrir des impôts ou des coûts d'exercice plutôt que vendues sur le marché libre.

Après cette retenue, Neeleman détient toujours 112 593 actions directement et 756 235 actions indirectement via une fiducie et une LLC familiale, portant sa détention totale à environ 868 828 actions. La cession représente environ 0,12 % de ses avoirs totaux, ce qui suggère aucun changement significatif dans l’alignement des initiés.

Le tableau II présente trois attributions d’options entièrement acquises avec des prix d’exercice de 41,28 $, 61,72 $ et 73,61 $, couvrant un total combiné de 49 462 actions encore en circulation et immédiatement exerçables.

Aucune autre vente, achat ou exercice de dérivés n’a été signalé. Étant donné la faible taille et la nature fiscale de la transaction, le dépôt est opérationnellement et financièrement sans importance pour les actionnaires de HQY.

Ein am 08.07.2025 eingereichtes Formular 4 offenbart, dass Stephen Neeleman, Gründer, Vizevorsitzender und Direktor von HealthEquity, Inc. (HQY), am 03.07.2025 1.049 Stammaktien veräußert hat zu einem durchschnittlichen Preis von $100,8721 unter dem Transaktionscode "F", was darauf hinweist, dass die Aktien einbehalten wurden, um Steuern oder Ausübungskosten zu decken, und nicht im offenen Markt verkauft wurden.

Nach dem Einbehalt hält Neeleman weiterhin 112.593 Aktien direkt und 756.235 Aktien indirekt über einen Trust und eine Familien-LLC, womit sein Gesamtbesitz bei etwa 868.828 Aktien liegt. Die Veräußerung entspricht etwa 0,12 % seines Gesamtbestands, was auf keine wesentliche Änderung der Insider-Ausrichtung hindeutet.

Tabelle II zeigt drei vollständig unverfallene Optionszuteilungen mit Ausübungspreisen von 41,28 $, 61,72 $ und 73,61 $, die zusammen 49.462 Aktien umfassen, die noch ausstehen und sofort ausgeübt werden können.

Es wurden keine weiteren Aktienverkäufe, Käufe oder Derivateausübungen gemeldet. Angesichts der geringen Größe und der steuerlichen Natur der Transaktion ist die Meldung für HQY-Aktionäre operativ und finanziell unerheblich.

Positive
  • Insider retains a substantial stake of roughly 868,828 shares, maintaining strong alignment with shareholders.
  • All reported stock options are fully vested, indicating the executive has long-term exposure to HQY's share price.
Negative
  • Insider disposed of 1,049 shares, although the sale appears tax-related and immaterial in size.

Insights

TL;DR: Tax-withholding sale of 1,049 shares; insider still owns ~868k—neutral impact.

The Form 4 shows a routine, code-F disposal by founder Stephen Neeleman. Because the 1,049 shares represent a fraction of his holdings and were surrendered for tax purposes, the sale does not signal a shift in sentiment or alter ownership control. Neeleman's sizeable remaining stake and fully vested, in-the-money options suggest continued alignment with shareholder interests. From a market-impact standpoint, the filing is informational rather than catalytic.

TL;DR: Minor, compliance-driven share withholding; governance posture unchanged.

The transaction code and small volume indicate a standard tax-settlement event following equity vesting. There is no evidence of strategic divestiture or governance concern. Insider still controls over 868k shares through direct and related entities, maintaining long-term incentive alignment. Consequently, I deem the disclosure not impactful on governance risk or shareholder influence.

Un modulo Form 4 presentato il 08/07/2025 rivela che Stephen Neeleman, fondatore, vicepresidente e direttore di HealthEquity, Inc. (HQY), ha ceduto 1.049 azioni ordinarie il 03/07/2025 a un prezzo medio di $100,8721 con codice di transazione "F", indicando che le azioni sono state trattenute per coprire tasse o costi di esercizio, e non vendute sul mercato aperto.

Dopo questa trattenuta, Neeleman detiene ancora direttamente 112.593 azioni e 756.235 azioni indirettamente tramite un trust e una LLC familiare, portando la sua proprietà totale a circa 868.828 azioni. La cessione rappresenta circa lo 0,12% del suo patrimonio complessivo, suggerendo nessun cambiamento significativo nell’allineamento interno.

La Tabella II mostra tre opzioni completamente maturate con prezzi di esercizio di $41,28, $61,72 e $73,61, relative a un totale combinato di 49.462 azioni ancora in essere e immediatamente esercitabili.

Non sono state segnalate altre vendite, acquisti o esercizi di derivati. Considerata la dimensione ridotta e la natura fiscale della transazione, la comunicazione è operativamente e finanziariamente irrilevante per gli azionisti di HQY.

Un Formulario 4 presentado el 08/07/2025 revela que Stephen Neeleman, fundador, vicepresidente y director de HealthEquity, Inc. (HQY), dispuso de 1,049 acciones ordinarias el 03/07/2025 a un precio promedio de $100.8721 bajo el código de transacción "F", lo que indica que las acciones fueron retenidas para cubrir impuestos o costos de ejercicio y no vendidas en el mercado abierto.

Tras la retención, Neeleman sigue poseyendo 112,593 acciones directamente y 756,235 acciones indirectamente a través de un fideicomiso y una LLC familiar, dejando su propiedad total en aproximadamente 868,828 acciones. La disposición representa aproximadamente el 0,12 % de su tenencia total, lo que sugiere que no hay un cambio material en la alineación interna.

La Tabla II muestra tres concesiones de opciones completamente adquiridas con precios de ejercicio de $41.28, $61.72 y $73.61, que cubren un total combinado de 49,462 acciones que permanecen vigentes y son inmediatamente ejercitables.

No se reportaron otras ventas, compras o ejercicios de derivados. Dado el tamaño reducido y la naturaleza relacionada con impuestos de la transacción, la presentación es operativa y financieramente insignificante para los accionistas de HQY.

2025년 7월 8일 제출된 Form 4에 따르면, HealthEquity, Inc. (HQY)의 창립자이자 부회장 겸 이사인 Stephen Neeleman이 2025년 7월 3일에 평균 가격 $100.87211,049주 보통주를 처분했으며, 거래 코드 "F"는 주식이 공개 시장에서 판매된 것이 아니라 세금 납부나 행사 비용 충당을 위해 원천징수되었음을 나타냅니다.

원천징수 후, Neeleman은 직접 112,593주와 신탁 및 가족 LLC를 통해 간접적으로 756,235주를 계속 보유하여 총 소유 주식 수가 약 868,828주에 이릅니다. 이번 처분은 전체 보유 주식의 약 0.12%에 해당하며, 내부자 지분 변동이 크지 않음을 시사합니다.

표 II에는 행사가격이 각각 $41.28, $61.72, $73.61인 완전히 취득된 세 가지 옵션 부여가 나와 있으며, 총 49,462주가 아직 남아 즉시 행사 가능합니다.

다른 주식 매도, 매수 또는 파생상품 행사는 보고되지 않았습니다. 거래 규모가 작고 세금 관련 거래임을 고려할 때, 이 신고는 HQY 주주들에게 운영적 및 재무적으로 중요하지 않은 사항입니다.

Un formulaire 4 déposé le 08/07/2025 révèle que Stephen Neeleman, fondateur, vice-président et administrateur de HealthEquity, Inc. (HQY), a cédé 1 049 actions ordinaires le 03/07/2025 à un prix moyen de 100,8721 $ sous le code de transaction "F", indiquant que les actions ont été retenues pour couvrir des impôts ou des coûts d'exercice plutôt que vendues sur le marché libre.

Après cette retenue, Neeleman détient toujours 112 593 actions directement et 756 235 actions indirectement via une fiducie et une LLC familiale, portant sa détention totale à environ 868 828 actions. La cession représente environ 0,12 % de ses avoirs totaux, ce qui suggère aucun changement significatif dans l’alignement des initiés.

Le tableau II présente trois attributions d’options entièrement acquises avec des prix d’exercice de 41,28 $, 61,72 $ et 73,61 $, couvrant un total combiné de 49 462 actions encore en circulation et immédiatement exerçables.

Aucune autre vente, achat ou exercice de dérivés n’a été signalé. Étant donné la faible taille et la nature fiscale de la transaction, le dépôt est opérationnellement et financièrement sans importance pour les actionnaires de HQY.

Ein am 08.07.2025 eingereichtes Formular 4 offenbart, dass Stephen Neeleman, Gründer, Vizevorsitzender und Direktor von HealthEquity, Inc. (HQY), am 03.07.2025 1.049 Stammaktien veräußert hat zu einem durchschnittlichen Preis von $100,8721 unter dem Transaktionscode "F", was darauf hinweist, dass die Aktien einbehalten wurden, um Steuern oder Ausübungskosten zu decken, und nicht im offenen Markt verkauft wurden.

Nach dem Einbehalt hält Neeleman weiterhin 112.593 Aktien direkt und 756.235 Aktien indirekt über einen Trust und eine Familien-LLC, womit sein Gesamtbesitz bei etwa 868.828 Aktien liegt. Die Veräußerung entspricht etwa 0,12 % seines Gesamtbestands, was auf keine wesentliche Änderung der Insider-Ausrichtung hindeutet.

Tabelle II zeigt drei vollständig unverfallene Optionszuteilungen mit Ausübungspreisen von 41,28 $, 61,72 $ und 73,61 $, die zusammen 49.462 Aktien umfassen, die noch ausstehen und sofort ausgeübt werden können.

Es wurden keine weiteren Aktienverkäufe, Käufe oder Derivateausübungen gemeldet. Angesichts der geringen Größe und der steuerlichen Natur der Transaktion ist die Meldung für HQY-Aktionäre operativ und finanziell unerheblich.

Air Products & Chemicals, Inc. false 0000002969 0000002969 2025-07-07 2025-07-07 0000002969 us-gaap:CommonStockMember 2025-07-07 2025-07-07 0000002969 apd:A0500NotesDue2028Member 2025-07-07 2025-07-07 0000002969 apd:A2.950NotesDue2031Member 2025-07-07 2025-07-07 0000002969 apd:M0.800EuroNotesDue20322Member 2025-07-07 2025-07-07 0000002969 apd:M3.250EuroNotesDue20321Member 2025-07-07 2025-07-07 0000002969 apd:A4000NotesDue2035Member 2025-07-07 2025-07-07 0000002969 apd:A3.450NotesDue2037Member 2025-07-07 2025-07-07
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 7, 2025

 

 

Air Products and Chemicals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   001-04534   23-1274455
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

1940 Air Products Boulevard Allentown,

Pennsylvania 18106-5500

(Address of principal executive offices and zip code)

(610) 481-4911

Registrant’s telephone number, including area code

not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $1.00 per share   APD   New York Stock Exchange
0.500% Euro Notes due 2028   APD28   New York Stock Exchange
2.950% Euro Notes due 2031   APD31   New York Stock Exchange
0.800% Euro Notes due 2032   APD32   New York Stock Exchange
3.250% Euro Notes due 2032   APD32B   New York Stock Exchange
4.000% Euro Notes due 2035   APD35   New York Stock Exchange
3.450% Euro Notes due 2037   APD37   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 7, 2025, Sean D. Major resigned as Executive Vice President, General Counsel and Secretary of Air Products and Chemicals, Inc. (the “Company”), effective July 11, 2025. Mr. Major’s successor will be named at a later date.

Mr. Major will receive severance and other benefits in accordance with the Company’s Executive Separation Program. The terms of the Executive Separation Program were disclosed in the Company’s definitive proxy statement for its 2025 Annual Meeting of Stockholders, which was filed with the United States Securities and Exchange Commission on December 3, 2024.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Air Products and Chemicals, Inc.
      (Registrant)

Date: July 8, 2025

    By:  

/s/ Melissa N. Schaeffer

      Melissa N. Schaeffer
      Executive Vice President and
      Chief Financial Officer

FAQ

How many HQY shares did Stephen Neeleman sell?

He disposed of 1,049 common shares at $100.8721 on 07/03/2025.

What percentage of his total holdings was sold?

Approximately 0.12 % of his combined direct and indirect ownership.

Why was transaction code "F" used in the filing?

Code F denotes shares withheld to cover tax or exercise costs, not an open-market sale.

How many HQY shares does Neeleman still own after the transaction?

He owns 112,593 shares directly and 756,235 shares indirectly, totaling about 868,828.

Were any stock options exercised in this Form 4?

No. The filing lists 49,462 fully vested options that remain outstanding but were not exercised.
Air Prods & Chems Inc

NYSE:APD

APD Rankings

APD Latest News

APD Latest SEC Filings

APD Stock Data

64.95B
221.67M
0.39%
90.98%
2.13%
Specialty Chemicals
Industrial Inorganic Chemicals
Link
United States
ALLENTOWN